NCT01115556View on ClinicalTrials.gov

A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Age Related Macular Degeneration
Interventions
DRUG

Ranibizumab

2.0 mg

DRUG

Ranibizumab

0.5 mg

Trial Locations (1)

10022

Vitreous Retina Macula Consultants of New York, New York

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Vitreous -Retina- Macula Consultants of New York

OTHER